AI-Designed GIPR Blocker Shows 18x Better Absorption in Obesity Drug Race
Insilico Medicine's ISM1354 blocks the GIP receptor to cut fat while preserving muscle, showing strong safety margins in animal studies.
Summary
Insilico Medicine has nominated ISM1354, an AI-designed small molecule that blocks the GIP receptor, as a preclinical candidate for obesity and type 2 diabetes. At the same dose as a rival compound, ISM1354 delivered at least 18 times more drug into the bloodstream. Oral bioavailability ranged from 75% to 104% across multiple animal species. The molecule also showed a roughly 45-fold safety margin in monkeys and far lower liver toxicity than the comparison compound in lab tests. The strategy pairs GIPR blocking with existing GLP-1 drugs like semaglutide — an approach designed to burn fat while protecting muscle mass. The drug was developed using Insilico's Chemistry42 generative AI platform, which filtered risky candidates early using a liver-injury prediction model. No human trials have begun yet.
Detailed Summary
Obesity pharmacology is shifting fast, and AI drug design is now claiming a seat at the table. Insilico Medicine has nominated ISM1354, a small-molecule GIPR antagonist, as its next preclinical candidate targeting obesity and type 2 diabetes. The move matters for longevity-minded readers because excess adiposity accelerates aging, and the muscle-preserving potential of GIPR blockade addresses a key weakness of current GLP-1 therapies — the risk of losing lean mass alongside fat.
The headline finding is pharmacokinetic: at an equivalent dose, ISM1354 produced at least 18 times greater plasma drug exposure compared to a clinical-stage benchmark compound. Oral bioavailability reached 75–104% across mice, rats, dogs, and monkeys — unusually consistent across species, which strengthens confidence in translational predictions. An earlier GIPR candidate from the same company, ISM0676, produced up to 31.3% weight loss in humanized mice when combined with semaglutide, and ISM1354 is reported to match that efficacy profile while improving safety.
Safety data are central to this nomination. Several GIPR candidates have recently failed clinical trials due to toxicity. ISM1354 showed substantially weaker inhibition of the liver transporter OATP1B1 — a known safety signal — and maintained cell viability in human liver cells at concentrations up to 200 μM, while the comparison compound showed toxicity at roughly 25 μM. In a non-GLP monkey toxicology study, the molecule was well tolerated with a calculated safety margin of approximately 45-fold.
The drug was discovered using Chemistry42, Insilico's generative chemistry platform, combined with an AI liver-injury prediction model to eliminate risky candidates early in the design cycle. This accelerated iteration is part of a broader company record: 10 preclinical nominations in nine months of 2026.
Critical caveats remain. No human data exist for ISM1354. The comparison compound is unnamed, limiting independent verification. All safety and efficacy data were generated by the company itself, and preclinical results frequently do not replicate in humans — a sobering reality for any obesity drug candidate entering an already competitive field.
Key Findings
- ISM1354 achieved at least 18-fold greater plasma drug exposure than a clinical-stage GIPR rival at the same dose.
- Oral bioavailability ranged from 75% to 104% across four animal species, suggesting strong and consistent absorption.
- Human liver cell viability was maintained up to 200 μM, versus toxicity at ~25 μM for the comparison compound.
- A 45-fold safety margin was calculated in monkey toxicology studies, supporting progression to formal GLP studies.
- Combining GIPR blockade with GLP-1 drugs aims to preserve muscle mass during fat loss — a key aging-related benefit.
Methodology
This is a news report based on a company press release from Insilico Medicine, not a peer-reviewed publication. Evidence is preclinical — animal pharmacokinetic and toxicology studies plus in vitro liver cell assays — all conducted and reported by the company. The comparison compound is unnamed, limiting independent verification.
Study Limitations
All data are company-generated and preclinical; no peer-reviewed publication has been cited. The benchmark compound is unnamed, preventing independent comparison. Preclinical bioavailability and safety results frequently fail to translate to humans, and the obesity drug pipeline has a high attrition rate at this stage.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: